Trial Profile
Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2015
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics
- Acronyms BOSTRO
- 26 Aug 2015 New trial record